# Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders

> **NCT07685678** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhongming Qiu** · enrollment: 20 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disease (NMOSD)
- Ripertamab

## Interventions

- **DRUG:** Ripertamab

## Key facts

- **NCT ID:** NCT07685678
- **Lead sponsor:** Zhongming Qiu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2030-01-01
- **Final completion:** 2030-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07685678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07685678, "Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07685678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*